secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001493152-25-028619
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma awards CEO $242K STI, $915K transaction award, and 62,500 PSUs
--------------------------------------------------------------------------

- CEO Erez Aminov receives $242,258 short-term incentive payout for 2025 performance; additional $80,753 contingent on Phase 1 study completion.
- Transaction advisory award of $915,000 approved for negotiating SKNY acquisition; payable in cash, equity, or both at CEO's election.
- 62,500 performance share units issued and immediately vested upon achievement of first market capitalization milestone under LTI plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225028619/0001493152-25-028619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225028619/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer